BersaChem Grants Exclusive to Genesis Technology Group to Source Manufacturing and Distribution Partner in China.

Business Editors/Health/Medical Writers

BOCA RATON, Fla.--(BUSINESS WIRE)--March 8, 2004

"X-Teril(R), a patented institutional disinfectant, could combat

avian flu, SARS and other airborne diseases in China."

Genesis Technology Group, Inc. (OTCBB:GTEC) announced today the signing of a letter of intent with BersaChem, Inc., a US-based healthcare company that has developed and holds a US-patented proprietary formula for X-Teril(R), a high level disinfectant solution. Genesis has secured a 3-month renewable exclusive to source a manufacturing and distribution partner in China. Upon securing an acceptable joint venture partner, Genesis could seek a long-term contract for exclusive manufacturing and marketing rights in China.

Mr. Bernardo Birnbaum, BersaChem president, commented: "In considering a marketing strategy for China, we were impressed by Genesis' history and ability to effectively transfer technologies. X-Teril(R) is ideally suited for Chinese hospitals and institutions. X-Teril(R), a patented disinfectant that has met all compliance requirements from the Venezuelan Ministry of Health, could combat avian flu, SARS and other airborne diseases in China. We have contracted with Genesis to introduce this important product line to the world's most dynamic market."

Mr. Gary L. Wolfson, Genesis CEO, observed: "Based on market research by our Shanghai office, we are confident that X-Teril(R) could become a market leader in China. The next few months will afford Genesis an opportunity to construct a China initiative for this product line. The need for such disinfectants is critical, where the outbreak of disease has become an increasingly serious concern.

"As a timely example, the Ministry of Communications reported last month that, by instituting strict disinfectant measures for vessels and vehicles, it will make every effort to ensure that bird flu will not spread. In Beijing, the city's largest road passenger transport company, Beijing Long-Distance Passenger Transport Company, resumed daily disinfection for all of its vehicles and bus stations," informed Mr. Wolfson. (For more information, refer to http://www.chinadaily.com.cn/en/doc/2004-02/05/content_303161.htm)

About BersaChem, Inc.

BersaChem, Inc., with headquarters in Hallandale Beach, Florida, has developed and holds a US-patented proprietary formula for X-Teril(R), a High Level Disinfectant Solution, which is non-toxic, non-corrosive, non-irritant solution of Lauryl-Dimethyl-Benzyl-Ammonium-Bromide (LDBAB). X-Teril(R) has met all compliance requirements from the Venezuelan Ministry of Health and is presently seeking FDA compliance for free sale of its cosmetic and OTC formulations. It has also applied to Mexican Health Authorities for equivalent compliance and clinical sanitary permits. This unique product is a one-step cold disinfecting agent that destroys 99.99% of susceptible microorganisms in seconds. A wide range of formulations has been developed for the clinical, veterinary, cosmetic and OTC applications. For more information, visit http://www.xteril.com

About Genesis Technology Group, Inc.

Genesis Technology Group is a business development firm that fosters bilateral commerce between companies in the West with those in China. Genesis has created successful profit centers in product development, manufacturing, distribution, joint ventures and operational services. The Company has fully staffed offices in the United States, Germany, and China. Genesis has established effective working relationships with various governmental agencies, public institutions, and private industries in China. In addition, the company acquires and invests in innovative technology companies in China or forms joint ventures with both American and elite Chinese companies, focusing on emerging technology industries including, but not limited to, nanotechnology, biotech, wireless telecommunication, information systems, environmental protection and biomedicine technologies. For more information, visit http://www.genesis-technology.net

This announcement contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.